Ask AI

Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

In this online educational program CCO’s expert faculty explore optimal care for patients with AML including predictive/prognostic factors to consider in selecting treatment for AML management of newly diagnosed AML treatment of relapsed/refractory disease and novel agents that may affect care in the near future.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Supporters

Supported by educational grants from

Astellas Text

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals, Inc.

Pfizer, Inc.